media – Page 3 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Amino acid metabolism shapes the tumor immune microenvironment and therapy response

The tumor microenvironment is not just a site of cancer growth—it is a high-stakes metabolic contest where tumor and immune cells vie for limited resources. Amino acids, once seen as passive nutrients, are now known to steer cell fate, immune suppression, and resistance to immunotherapy. Tumors often win this battle by monopolizing amino acids, crippling the metabolism of nearby T cells and macrophages. Recent advances have illuminated how this biochemical imbalance hinders immune surveillance and fosters tumor progression. Due to these challenges, there is a growing urgency to explore how amino acid dynamics influence cancer immunity and identify new therapeutic targets within this hidden battleground. In a new review (DOI: 10.20892/j.issn.2095-3941.2025.0115) published in Cancer Biology & Medicine, scientists from Tongji University Cancer Center explored how amino acid metabolism governs the intricate dialogue between cancer cells and immune defenses. The paper charts a comprehensive map of how amino acid sensing, transport, ...
- Source: drugdu
- 50
- August 18, 2025
The company is not involved in the vaccine business

Everyday AI Newsflash: An investor asked on the investor interaction platform: Has the company participated in the research and development of an AIDS vaccine? Does the company have this technology? Tiantan Biological (600161.SH) stated on the investor interaction platform on August 15 that the company is not involved in the vaccine business. The company’s main business is the research and development, production and sales of blood products, and it is in the blood products industry. At present, the company has launched three major categories of products, namely human albumin, human immunoglobulin and human coagulation factor, as well as recombinant coagulation factor products. https://finance.eastmoney.com/a/202508153485469676.html
- Source: drugdu
- 42
- August 18, 2025
Shingrix is superior to HZ/su vaccine in head-to-head comparison

On August 18th, Green Bamboo Biology-B (02480) announced that a head-to-head comparative study of its core product LZ901 and the recombinant glycoprotein E(gE) subunit vaccine HZ/su vaccine (Shingrix®) was conducted, and positive immunogenicity and safety data were obtained. This study recruited 301 healthy adults aged 50 and above. The results showed that LZ901 was superior to the HZ/su vaccine in both cellular immunogenicity and safety. In terms of specific immunogenicity results, LZ901 did not perform worse than the HZ/su vaccine in CD4+ and CD8+T cell immune responses. The proportion of gE specific CD4+T cell responders was 83.0%, while that of the HZ/su vaccine was 58.1%. The proportion of gE specific CD8+T cell responders was 46.8%, and that of HZ/su vaccine was 8.8%. In terms of safety, the adverse reaction rate of LZ901 was 41.1%, significantly lower than 87.9% of the HZ/su vaccine, and most of the reported reactions were mild ...
- Source: drugdu
- 46
- August 18, 2025
Soaring 1515%! The “champion of growth rate” among innovative drugs has made its debut

Amid the ever-changing capital market, the increase in the share price of Beihai Kangcheng is undoubtedly a remarkable and phenomenon-level event. Starting from a low of HK $0.13 at the beginning of this year, the share price of Cansino Biologics has been surging. As of the close of trading on August 13th, it has soared to HK $2.1, achieving an astonishing growth of over 15 times compared to the beginning of the year, with an increase of as high as 1,515%. This astonishing increase has become a hot topic of discussion in the capital market. In the current highly competitive pharmaceutical industry and with rapidly changing policy environments, why has the share price of Cansino Biologics been able to soar and become a favorite of the capital market? Good news keeps coming The share price of Beihai Kangcheng has soared, mainly due to the recent dual positive factors. On August ...
- Source: drugdu
- 42
- August 18, 2025
Zhonghui Bio-B recombinant RSV vaccine approved by FDA and CDE

On August 17, Zhonghui Bio-B (02627) announced that its independently developed recombinant respiratory syncytial virus vaccine (CHO cells) (adjuvanted) had received approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration and the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. This vaccine was developed to target respiratory syncytial virus (RSV), a significant cause of respiratory infections in infants, the elderly, and immunocompromised individuals. According to the announcement, the company’s vaccine demonstrated higher pre-F protein expression levels (approximately 1,000 to 1,500 mg/L) in preclinical studies than the marketed recombinant RSV vaccine (approximately 600 to 800 mg/L for the marketed product). Furthermore, after 14 days at 40°C, the company’s pre-F protein activity remained above 95%, while the marketed product’s activity decreased to approximately 50%. This demonstrates that the company’s vaccine is more stable and immunogenic than similar products. While the company ...
- Source: drugdu
- 39
- August 18, 2025
【EXPERT Q&A】How can one query the natural medicines approved in the past decade and their sources through the FDA drug approval database?

Drugdu.com expert’s response: To query FDA-approved natural drugs and their sources over the past decade through the FDA drug approval databases, the following systematic workflow can be followed, integrating FDA official resources with natural product classification logic for efficient retrieval: I. Define Search Objectives and Natural Drug Categories Natural drugs typically refer to active ingredients directly derived from plants, microorganisms, marine organisms, or minerals, as well as their structurally modified derivatives. Key focus areas include: Plant-derived: Examples include paclitaxel (from Pacific yew) and artemisinin (from sweet wormwood). Microorganism-derived: Examples include erythromycin (from actinomycetes) and cyclosporine (from fungi). Marine-derived: Examples include trabectedin (from sea squirts) and eribulin (from sponges). II. Leverage FDA Core Databases for Screening Drugs@FDA Database Steps: Access the database and select “Advanced Search”. Set the “Approval Date Range” to the past decade (e.g., January 1, 2015, to December 31, 2025). Enter natural product-related keywords in the “Active Ingredient” ...
- Source: drugdu
- 58
- August 18, 2025
Quanguo Fund conducts research on Shenlian Biotechnology, and Shizhiyuan is conducting a phase II clinical trial of chronic spontaneous urticaria in China

According to the disclosed institutional research information, Quanguo Fund conducted research on listed company Shenlian Biotechnology from August 6, 2025 to August 8, 2025. Attached research content: 1、 An introduction was given on the recent business situation of the company, the research and development progress of new products such as multi valent vaccines, the company’s layout and positioning in the field of human biological products, and the future coordinated development strategy of animal protection and human drug use. 2、 Main communication Q&A Quan Guo Fund Q1. Please introduce the basic situation of Yangzhou Shizhiyuan Biotechnology Co., Ltd. Answer: Yangzhou Shizhiyuan Biotechnology Co., Ltd. is a high-tech biopharmaceutical enterprise established in October 2020. At the beginning of its establishment, it was an important biopharmaceutical development base set up by the United Biomedical, Inc. (UBI) group in mainland China, focusing on innovative drug development, clinical approval, project management, and promoting clinical trial ...
- Source: drugdu
- 51
- August 15, 2025
Respiratory viruses awaken dormant breast cancer cells and raise relapse risk

In a recent study published in Nature, an international team of researchers showed that respiratory viral infections awaken dormant breast cancer cells in the lungs. Breast cancer is the most prevalent cancer in females and the second leading cause of cancer-related deaths in the United States (US). Disseminated cancer cells (DCCs) can remain dormant for years after initial remission before metastatic relapse. The tumor microenvironment and cell-intrinsic factors determine whether metastatic cells progress or remain dormant. Notably, microenvironmental disturbances can be sufficient to increase metastasis. Respiratory viral infections are common, with seasonal flu affecting over one billion people yearly. These infections are usually associated with pulmonary inflammation along with an increase in inflammatory cytokines (interferons [IFNs] and interleukin 6 [IL-6]) and expansion of immune cells, such as macrophages, T cells, and neutrophils. Such inflammatory mechanisms have been reported as regulators of metastatic processes. The study and findings In the present ...
- Source: drugdu
- 50
- August 15, 2025
Got the Sniffles? Here’s What to Know About Summer Colds and the COVID-19 Variant Called Stratus

Summer heat, outdoor fun … and cold and flu symptoms? The three may not go together in many people’s minds: partly owing to common myths about germs and partly because many viruses really do have lower activity levels in the summer. But it is possible to get the sniffles — or worse — in the summer. Federal data released Friday, for example, shows COVID-19 is trending up in most states, with emergency department visits up among people of all ages. Here’s what to know about summer viruses. How much are colds and flu circulating right now? The number of people seeking medical care for three key illnesses — COVID-19, flu and respiratory syncytial virus, or RSV — is currently very low, according to data from the Centers for Disease Control and Prevention. Flu is trending down and RSV has been steady. But COVID-19 is trending up in most U.S. states. ...
- Source: drugdu
- 49
- August 15, 2025
The biochemical raw material of Vonola fumarate has been approved for marketing

People’s Finance News, August 13th: China National Pharmaceutical Group (600056) announced on the evening of August 13th that its wholly-owned subsidiary, Tianfang Pharmaceutical, has received the “Notice of Approval for the Marketing Application of Vonoprazan fumarate” issued by the National Medical Products Administration. This medicine is mainly used to treat reflux esophagitis. Combined with appropriate antibiotics to eradicate Helicobacter pylori. In addition, Tianfang Pharmaceutical has recently received the “European Pharmacopoeia Applicability” certificate for clindamycin phosphate approved and issued by the European Agency for the Quality of Medicines. This medicine is a lincomycin antibiotic, mainly used for infections caused by Gram-positive bacteria and anaerobic bacteria.
- Source: drugdu
- 49
- August 15, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.